The Promise and Challenges of Personalized Medicine in Hematologic Malignancies

Journal Title: Journal of Hematology & Thrombosis - Year 2015, Vol 1, Issue 2

Abstract

Personalized medicine is a rapidly emerging medical model that proposes individually customized healthcare to potentially increase the quality of clinical care and reduce health care costs. The key to the success of personalized medicine is development of diagnostics and therapeutics based upon molecular, genetic, epigenetic, pharmacogenomic and metabolic features of individual patients. Personalized medicine in oncology seeks to individualize cancer care and treatment decisions based upon features unique to each patient and each patient’s tumor. Medical decisions are then being tailored to the individual patient with the hope of providing improved quality-of-life and overall survival. Diagnostic testing is employed to select appropriate and optimal therapies based upon the context of each patient’s genetic content or other molecular or cellular tests. The concept of personalized medicine hopes to not only enhance the patient quality of life and survival but also to lower overall healthcare costs through early-detection, prevention, accurate risk assessments and more efficient health care delivery systems. However, personalized approaches in oncology face major, complex scientific and economic problems. Here, we discuss certain scientific and economic challenges that face the future of personalized medicine in the treatment of hematologic malignancies.

Authors and Affiliations

James J Driscoll

Keywords

Related Articles

Accidental and Surreptitious Intake of Oral Anticoagulants Including Older and Newer Agents - A Diagnostic Dilemma

The newer oral anticoagulants including dabigatran, rivaraxoban, apixaban and edoxaban are replacing warfarin in the management of atrial fibrillation and venous thromboembolism. Accidental and surreptitious overdose of...

Bone Scintigraphy Scanning Safety and Necessity for Silent and Multifocal Osteonecrosis in Sickle Cell Disease

Sickle cell disease is a congenital autosomal recessive disease. The predominant pathophysiological feature is vaso cclusion, which leads to acute and chronic complications. Multifocal and silent progressive osteonecrosi...

Differences in Circulating Endothelial Progenitor Cells among Childhood Cancer Survivors Treated with and without Radiation

Radiation during childhood cancer treatment increases the propensity to atherosclerotic cardiovascular disease among adult survivors of childhood cancer. This is thought to be mediated through the damage to the underlyin...

Effects of Heparin Therapy on Hexagonal Lipid Neutralization Test

In this retrospective study; we evaluate the effects of heparin therapy on hexagonal lipid neutralization test. We identified 8000 patients in our hospital system that had been evaluated for lupus anticoagulants. Among t...

Evaluation of Schistocytosis in Patients Treated with Dialysis

Schistocytes are associated with micro angiopathic hemolytic processes. In this retrospective study; we evaluate the association ofschistocytosis in the peripheral blood smear of patients before and after dialysis. We id...

Download PDF file
  • EP ID EP246516
  • DOI 10.13188/2380-6842.1000007
  • Views 158
  • Downloads 0

How To Cite

James J Driscoll (2015). The Promise and Challenges of Personalized Medicine in Hematologic Malignancies. Journal of Hematology & Thrombosis, 1(2), 1-3. https://europub.co.uk/articles/-A-246516